

NUS MEDICINE • CHINA ACADEMIC PARTNERSHIP SUMMIT

PROGRAMME BOOKLET



21st October 2026



Geneo Bridge+, Nexus Hall 1 & 2



CONTENT PAGE

Page	Content
01	Welcome Message
02 -05	Event Venue
06	Event Floorplan
07-09	Programme Rundown
10-19	Speaker List
20-24	Sponsor & Organizers

WELCOME MESSAGE

by Prof. Chong Yap Seng



Dear Colleagues, Partners, and Friends,

It is my great pleasure to welcome you to the inaugural **NUS Medicine-China Academic Partnership Week 2026** — five days of scientific exchange, strategic dialogue, and celebration of the next generation of biomedical talent.

Science is the irrefutable bedrock of health and human progress. When science is given room to flourish, innovation becomes a lived reality; when societies anchor their decisions in evidence, lives are saved. In our own lifetime, we have seen how scientific rigour, coupled with ungrudging collaboration and urgent purpose, changed the course of a global crisis. That experience also taught us, with unmistakable clarity, that health of communities thousands of kilometres away is inseparable from the health of our own — we cannot improve the health of our nation, or of populations around the world, by working in isolation.

This gathering is a testament to the deepening bonds between **NUS Yong Loo Lin School of Medicine** and our esteemed partners at **Shanghai Jiao Tong University School of Medicine**, **Zhejiang University School of Medicine** and the **University of Manchester** — relationships built on shared curiosity, mutual respect, and a common mission to advance human health. Together, we recognise that global health challenges that transcend borders and disciplines demand a multinational and multidisciplinary response grounded, above all, in evidence.

Across three flagship events, our symposia convene leading minds across mutual areas of interest including Healthy Longevity, Precision Medicine, Cancer, Pandemic Preparedness, CAR-T, AI Medicine, Infectious Disease, Cardiovascular Diseases, and Women's Health, while inviting us to understand these themes through the lens of Asian contexts. Our Partnership Summit, in turn, looks to the future and explores how we can work together to translate science into service for good.

Over these five days, may we debate rigorously, listen generously, and collaborate freely. I am certain that this week of conversations will yield real impact and innovation and bring us closer to the healthier future we will build by standing with science, and by standing together.

Welcome to Singapore. I look forward to inspiring health for all, together with all of you.


Warm regards,



Chong Yap Seng
 Lien Ying Chow Professor in Medicine
 Dean, Yong Loo Lin School of Medicine, National University of Singapore





EVENT VENUE



BY CAR (DROP-OFF POINT)

Upon dropping off, (facing the fountain) turn right. You will see Building 1A, head inside and Bridge+ Geneo is located inside at Level 1.









BY CAR (DRIVE)


Upon turning into Science Park Drive, go one loop around the driveway and turn into the carpark on the left.

The carpark is located at 1 Science Park Dr, Singapore Science Park 1, Singapore 118221.

*Please note that parking is subjected to the venue's rates.





Take the lift from the carpark. Upon exiting, with Swensen's on your right, turn left and walk straight ahead towards Building 1A.






BY KENT RIDGE MRT CC24

From Kent Ridge MRT, please take Exit B. Walk via the underpass and take the escalator to Level 1 (Swensen's on the left). You will see Building 1A ahead. Bridge+ Geneo is located inside at Level 1





BY BUS


1A Science Park Dr 15151

Direct Services: 92, 92A (Loop from Buona Vista MRT).

Nearby (Buona Vista Flyover): 14, 33, 97, 166, 197, 963, 963e.



EVENT FLOORPLAN



PROGRAMME RUNDOWN

NUS Yong Loo Lin School of Medicine - China Academic Partnership Summit

DAY 3 - 21 OCTOBER 2026, WEDNESDAY

9:00 - 9:30 **Registration**

Session Chair/ Emcee: A/Prof Helen Zhou and Asst. Prof Harlon Yang Yiyuan

9:30 - 9:40 **Opening & Welcome Address by Professor Chong Yap Seng,
Dean, NUS Yong Loo Lin School of Medicine**

9:40 - 10:00 **Keynote Address by Professor Kishore Mahbubani,
Distinguished Fellow, Asia Research Institute (ARI),
National University of Singapore**

**- “Asia’s Scientific Century: Singapore as a Bridge Between
Asia and the West”**

10:00 - 10:20 **Keynote Address by Professor Howard Bauchner, Professor
of Pediatrics and Public Health, former Editor-in-Chief of
JAMA, Boston University Chobanian & Avedisian School of
Medicine**

**- “Publishing in High-Impact Journals: Opportunities and
Challenges”**

10:20 - 10:50 **Fireside Chat/Panel Discussion**

Moderator / Lead

- Professor Roger Foo

Panelists

- Professor Kishore Mahbubani
- Professor Chong Yap Seng
- Professor Howard Bauchner
- Adjunct Professor Tan Sze-Wee

10:50 - 11:10

Tea Break

11:10 - 12:10

Charting the Course	Academic - Industry Engagement Session
Session Chair: Prof Roger Foo (NUS)	Session Chair: Emanuel Dobrescu (NUS)
NUS Medicine China Partnerships Strategy (By Invitation Only)	<p><u>Adj A/Prof James Lee (NUS)</u> - <i>"MedTech Academic-Industry Collaborations at NUHS"</i></p> <p><u>Dr Yin Nah Teo</u>, Director, Scientific Research, Illumina Core R&D - <i>"Beyond the Genome with Multiomics: Unlocking Deeper Biology"</i></p> <p><u>Dr Hyundoo Hwang</u>, CEO, Bredis Healthcare Inc - <i>"From Discovery to Clinical-Grade Evidence: Bridging Industry and Academia for Blood Biomarkers in Neurodegenerative Diseases"</i></p> <p><u>Prof Wang Chunming (SJTU)</u> - <i>"Beyond Code and Compassion: Renji AI-Enabled Smart Hospital Development"</i></p>

12:10 - 13:30

Lunch + Poster Session & Judging

Session Chair: Dr. Shi Ruoyu (NUH)

**PATHFINDING CHINA: CLINICAL RESEARCH & LIFE SCIENCES
 AHEAD BY DR ANDREW LEE, DR YICHONG LI & PROF. TAN SZE WEE**

13:30 - 14:30

***“The Greater Bay Area as a Bidirectional Gateway for
 Clinical Development: Connecting Chinese and Global
 Clinical Research”, Dr. Yichong Li***

- Director, HK-Macau-Guangdong GBA International Clinical Trial Center

***“Clinical Development of a Non-Viral Extracellular Vesicle
 Therapy Gene Therapy for Rare Disease via the 818 Dual
 Track Regulatory Framework in China”, Dr. Andrew LEE***

- Deputy Director, HK-Macau-Guangdong GBA International Clinical Trial Center;
- Associate Professor, Peking University Shenzhen/Shenzhen Bay Laboratory

Session Chair: Prof Wei Tao (NUS)

14:30 - 15:30

***“Overview of Life Sciences Ecosystem in China - Biosparc as
 Singapore’s gateway to China”, Adj Prof. Tan Sze Wee***

- Advisor, Temasek Singapore Pte Ltd
- Adjunct Professor, Duke-NUS Medical School, Singapore
- Chairman, NUS Medicine Industry Advisory Board, Singapore

15:30 - 16:00

Tea Break + Poster Session & Judging

Session Chair: Emanuel Dobrescu (NUS)

16:00 - 16:30

Poster Prize Presentation by Professor Roger Foo, Vice Dean (Research), NUS Yong Loo Lin School of Medicine

16:30 - 17:00

Closing Address & Phototaking by Professor Roger Foo, Vice Dean (Research), NUS Yong Loo Lin School of Medicine



SPEAKER LIST

OPENING & WELCOME ADDRESS



Chong Yap Seng

- *Lien Ying Chow Professor in Medicine*
- *Dean, NUS Yong Loo Lin School of Medicine (NUS Medicine)*
- *Deputy Chief Executive (Education & Research), National University Health System*

National University of Singapore
 NUS Yong Loo Lin School of Medicine

BIOGRAPHY:


Professor Chong Yap Seng is the Dean of the Yong Loo Lin School of Medicine at the National University of Singapore. Since assuming the deanship in 2019, NUS Medicine has risen to 13th place in the 2026 Times Higher Education World University Rankings (Medical & Health) and 17th place in the 2026 QS World University Rankings for Medicine. His efforts to refocus medical education on health were recognised with an honorary doctorate from the University of Zurich. For his longstanding contributions to medical science and global health, he was conferred the ATOM Lifetime Outstanding Achievement Award for Healthcare.

As NUHS' Deputy Chief Executive (Education and Research), Professor Chong oversees academic and research development at all NUHS institutions. He also serves as Chief Clinical Officer at A*STAR's Institute for Human Development and Potential.

Professor Chong is the lead principal investigator of the landmark GUSTO and S-PRESTO birth cohort studies. He has co-authored nearly 700 research publications and received numerous awards, including the National Outstanding Clinician Scientist Award and the Public Administration Medal (Silver).

Driven by a lifelong belief in the power of science to optimise human potential, he was appointed Executive Director of Singapore's first RIE Grand Challenge on Maximising Healthy and Successful Longevity.

KEYNOTE ADDRESS



Kishore Mahbubani

Distinguished Fellow

**National University of
Singapore**
Asia Research Institute

TITLE OF THE TALK:

Asia's Scientific Century: Singapore as a Bridge for China and the World

BIOGRAPHY:

Kishore Mahbubani is a Distinguished Fellow at the Asia Research Institute (ARI) at the National University of Singapore (NUS). He has enjoyed two distinguished careers—as a diplomat and an academic.

From 1971 to 2004, Kishore served in the Singapore Foreign Service, with postings in Cambodia, Malaysia, Washington DC and New York. He twice served as Singapore's Ambassador to the UN and as President of the UN Security Council, and was Permanent Secretary at the Foreign Ministry from 1993 to 1998. For his distinguished service, he received the Public Administration Medal (Gold) in 1998.

In 2004, Kishore joined academia as Founding Dean of the Lee Kuan Yew School of Public Policy, NUS, serving until 2017. In 2019, he was elected an honorary international member of the American Academy of Arts and Sciences. A President's Scholar, he graduated with First-Class Honours in Philosophy and holds a Master's from Dalhousie University.

A prolific author, Kishore has published ten books, including *The Asian 21st Century* and his memoir, *Living the Asian Century*. He has received wide international recognition, twice named a Top Global Thinker by Foreign Policy, which described him as “the muse of the Asian century.”

KEYNOTE ADDRESS



Howard Bauchner

*Professor of Pediatrics and
Public Health*

**Boston University Chobanian
Avedisian School of Medicine**

TITLE OF THE TALK:

Publishing in High Impact Journals: Opportunities and Challenges

ABSTRACT:

Publishing in high impact journals is important for various reasons, including influencing science, clinical care, and public health, as well as enhancing an author's career. In this brief presentation I will explore opportunities and challenges.

BIOGRAPHY:

Howard Bauchner, MD is a Professor of Pediatrics and Public Health at Boston University Chobanian and Avedisian School of Medicine. He served as the 16th Editor in Chief of JAMA and the JAMA Network between 2011 and 2021 and Editor in Chief of Archives of Disease in Childhood between 2003 and 2011.

At JAMA Howard focused on publishing important and novel research articles including randomized clinical trials, opinion pieces, and special communications, improving and expanding clinical content, using electronic/digital approaches to enhance communication, ensuring a commitment to innovation and increasing diversity. During his tenure followers on social media increased from ~13,000 to ~1,200,000 and the electronic table of contents was distributed to over 1,000,000 individuals each week. In print, via eTOC, and social media content published by JAMA reached over 1.5M physicians worldwide each week. All 9 of the specialty journals were renamed (Archives of Pediatrics became JAMA Pediatrics, etc.), 4 new journals were launched - JAMA Oncology (2015), JAMA Cardiology (2016), and JAMA Network Open (2018); and JAMA Health Forum (2020/2021), the latter 2 are both fully open-access journals. Howard authored and recorded over 200 editorials and podcasts (including live-stream events) during his time at JAMA.

ACADEMIC – INDUSTRY ENGAGEMENT SESSION



James Lee Wai Kit

- *Adjunct Associate Professor, Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore*
- *Deputy Group Chief Technology Officer, Academic Innovation Office (AIO), National University Health System*

National University of Singapore

Department of Surgery, Yong Loo Lin School of Medicine

TITLE OF THE TALK:

MedTech Academic-Industry Collaborations at NUHS

BIOGRAPHY:

Dr Lee's core priority is delivering the best patient care through collaboration, education, and technology. He believes nurturing future doctors ensures sustained excellence across generations, while AI and big data serve as vital co-pilots to augment clinical decision-making.

A 2013 graduate of NUS Yong Loo Lin School of Medicine (Dean's List), Dr Lee completed his General Surgery residency at NUHS, obtaining MRCS (Edinburgh) in 2015 and MMed (Surgery) in 2019. He became an FRCS (Edinburgh) and accredited Specialist in General Surgery in 2020. His subspecialty is Endocrine Surgery, with expertise in minimally invasive thyroid surgery, non-invasive thyroid nodule ablation, and advanced parathyroid localisation.

Dr Lee is deeply committed to undergraduate and residency education. He serves as Surgery Undergraduate Deputy Education Director at NUS Medicine, Surgery Block Lead for LKCMedicine's Phase 3 programme, and Undergraduate Education Director and Associate Program Director for General Surgery Residency at Alexandra Hospital.

Passionate about healthcare informatics, he anchors the NGEMR setup at Alexandra Hospital's Department of Surgery and leads technology projects at NUHS Group Technology Office. He is currently Deputy Group Chief Technology Officer for the Academic Innovation Office, advancing clinical and educational applications of AI.

ACADEMIC – INDUSTRY ENGAGEMENT SESSION



Yin Nah Teo

*Director of Scientific Research in
the Core R&D organization*

Illumina

TITLE OF THE TALK:

Beyond the Genome with Multiomics: Unlocking Deeper Biology

ABSTRACT:

At Illumina, innovation is in our DNA. For more than 20 years, we've been at the forefront of next-generation sequencing, enabling scientists, clinicians and researchers across more than 140 countries to unlock the power of the genome. Our latest sequencing platforms - the NovaSeq™ X, NextSeq™ 2000 and MiSeq™ i100 - are transforming the way genomic data is generated. From advanced patterned flow cell engineering to streamlined onboard data analysis, we've made sequencing more accessible, more accurate and more affordable than ever before, helping accelerate discoveries that improve lives around the world.

Now, that same innovation is driving the future of multiomics research. Illumina's NGS technology has become the foundation for exploring biology at multiple levels, such as genomics, transcriptomics and epigenomics, providing a more complete view of health and disease. Through our innovation roadmap, we are developing tools that deliver greater resolution, faster turnaround and seamless data integration. From single-cell analysis to spatial transcriptomics and proteomics, we are creating the technologies and partnerships that will make multiomics discovery not just possible, but truly transformative.

We look forward to sharing with you where we're heading next in the field of multiomics, to deliver technology and products that can help accelerate your discoveries.

BIOGRAPHY:

Dr Yin Nah Teo is Director of Scientific Research in the Core R&D organization at Illumina, where she leads multidisciplinary teams developing next-generation genomics and multiomics technologies. Dr Teo received her PhD in Chemistry from Stanford University, where she specialized in molecular design of modified nucleic acids. She did her postdoctoral training with Dr Sydney Brenner, focusing on developing chemical and biochemical toolkits to interrogate biological systems.

Over more than a decade with Illumina, she has led global project teams involved in translating early-stage innovation into flagship sequencing platforms, including the NovaSeq™ X, NextSeq™ 2000 and MiSeq™ i100, systems that continue to expand the scale, speed, and accessibility of genomics discovery. More recently, her teams have also contributed to the latest multiomics technologies in 5-base sequencing and Illumina TruPath technology.

Recognized as a champion inventor at Illumina, Dr Teo is an inventor in more than 25 patent families and over 98 invention disclosures. She is particularly driven to bridging the gap between research and real-world applications, partnering across scientific, engineering, and operational domains to accelerate the path from concept to product.



ACADEMIC - INDUSTRY ENGAGEMENT SESSION



Hyundoo Hwang

• Chief Executive Officer

Bredis Healthcare Inc.

TITLE OF THE TALK:

From Discovery to Clinical-Grade Evidence: Bridging Industry and Academia for Blood Biomarkers in Neurodegenerative Diseases

ABSTRACT:

Blood-based biomarkers are reshaping how neurodegenerative diseases are detected and monitored, offering a scalable, minimally invasive alternative to brain imaging and cerebrospinal fluid testing. Genomic and high-plex proteomic platforms can identify candidates at unprecedented scale, but the bottleneck lies in generating reproducible, clinical-grade evidence in well-characterized cohorts.

Bredis Healthcare was built to close this gap. Its MFDS-designated GCLP cleanroom laboratory performs more than 50,000 analyses annually across over 560 biomarkers for more than 80 institutional partners in Korea and Singapore. Standardized SOPs and rigorous quality management deliver reproducible quantification at atomolar levels, where minor variations in the environmental and experimental parameters can change results.

Drawing on partnerships with leading Korean hospitals and cohorts — including 23 of the 47 tertiary hospitals and dementia cohorts of more than 15,000 participants — and the MACC at NUS, this talk will show how collaborations evolve from contract testing into joint discovery and clinical validation. It will propose a shared model in which academic cohorts, discovery platforms, and diagnostic developers connect through a quality-assured validation hub — one that gives each participating cohort an independent Asian validation population alongside a common measurement standard, accelerating the path from candidate biomarker to clinically deployable test across Asia.

BIOGRAPHY:

Dr. Hyundoo Hwang is the Founder and CEO of Bredis Healthcare Inc., a biotechnology company specializing in ultrasensitive biomarker analysis and translational research for neurodegenerative diseases. He earned his B.S., M.S., and Ph.D. in Bio and Brain Engineering from KAIST, receiving his doctorate with distinction. He then completed postdoctoral research at the Georgia Tech and joined as a tenured professor at Tec de Monterrey, where he led international research programs in biomedical engineering, diagnostics, and microfluidics.

Dr. Hwang has more than 20 years of experience spanning biotechnology, medical devices, manufacturing, regulatory affairs, and quality systems. He has led the development and commercialization of a variety of diagnostic and digital healthcare technologies, — including ultrasensitive blood biomarker assays, point-of-care diagnostics, wearable health monitoring systems, and digital therapeutics cleared by the FDA, CE IVDR, and Korea MFDS — and holds more than 70 patents filed or granted in Korea, the United States, China, Japan, and Europe, with over 60 peer-reviewed publications.

At Bredis Healthcare, he has built a quality-assured biomarker validation platform that connects hospitals, academic cohort programs, and industry partners in Korea and Singapore. His work focuses on turning promising biomarker candidates into clinically credible evidence for early detection and patient stratification.

ACADEMIC – INDUSTRY ENGAGEMENT SESSION



Wang Chunming

- Director, Office of International Affairs
- Director, Smart Hospital Development (Renji Hospital)

Shanghai Jiao Tong University
 School of Medicine

TITLE OF THE TALK:

Beyond Code and Compassion: Renji AI-Enabled Smart Hospital Development

ABSTRACT:

Renji Hospital Triple I exportable AI solution.

Over six years, its internet hospital accumulated over 14 million real doctor-patient dialogues and services. Those records trained AIDA, an AI Doctor Assistant now deployed across 19 disciplines. Separately, in the ICU, a critical care AI model monitors patients 24/7—offering treatment advice in 5 seconds and writing records in 1 minute.

In 2026, Renji earned the world's first DNV international quality certification for an internet hospital, proving its service standards and data security.

In June 2026, Renji led the “Smart Healthcare Going Global Initiative,” partnering with Global partners such as Mindray to draft a white paper guiding hospitals worldwide.

A 182-year-old hospital didn't chase scale. It moved early, built depth, and turned data into a global product.

The real moat in healthcare AI isn't scale—it's depth.

BIOGRAPHY:

Wang Chunming, Professor, Ph.D.

Major Concurrent Appointments:

- Vice Chair, Smart Healthcare Expert Committee, Chinese Institute of Electronics
- Director, Medical Operations Management Branch, Operations Research Society of China
- Standing Committee Member, Smart Healthcare Professional Committee, Chinese Association of Integrative Medicine
- Vice Chair, International Medical Services Branch, Shanghai Medical Association
- Committee Member, Medical Artificial Intelligence Management Professional Committee, Shanghai Hospital Association
- Committee Member, Internet Healthcare Committee, Shanghai Medical Association
- And positions in several other national and local professional committees

Career Achievements:

Having held diverse management roles in medical services, scientific research, and teaching at a large comprehensive public hospital, he focuses on interdisciplinary exploration and research in smart healthcare, artificial intelligence, internet hospitals, and international medical services. He has led over 20 projects, including those funded by the National Natural Science Foundation of China, published more than 40 papers in domestic and international journals, and holds 16 granted patents.

PATHFINDING CHINA: CLINICAL RESEARCH & LIFE SCIENCES AHEAD



Yichong Li

• Director

**Hong Kong-Macau-Guangdong
GBA International Clinical Trial
Center (BAY TRIAL)**

TITLE OF THE TALK:

The Greater Bay Area as a Bidirectional Gateway for Clinical Development: Connecting Chinese and Global Clinical Research

ABSTRACT:

The Guangdong-Hong Kong-Macao Greater Bay Area (GBA) is emerging as a strategic interface for cross-border clinical development. This talk will present the architecture of the GBA Clinical Trial Collaboration Platform, built around the “one institute, one centre” partnership between the Greater Bay Area International Clinical Trial Institute (GBAICTI) in Hong Kong and the Greater Bay Area International Clinical Trial Center (BAY TRIAL) in Shenzhen, co-located within the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone. The platform is designed to support two complementary needs: Chinese sponsors seeking internationally credible, multi-regional evidence for global expansion, and international sponsors needing compliant, predictable routes to generate evidence and reach patients in China. Key enablers include real-world evidence infrastructure, the new regulatory framework for novel biomedical technologies, and a growing pipeline of multi-ethnic and multi-regional trials. This presentation will discuss how the GBA model can move from pilot initiatives to a trusted operating system for clinical development across regulatory boundaries, ultimately helping Chinese innovation reach global markets and global innovation reach Chinese patients.

BIOGRAPHY:

Yichong Li, MD, is a Principal Investigator and Professor at the National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences. He earned his Master and Doctor degree of Medicine and from West China Medical Science Center, Sichuan University, and the Chinese Center for Disease Control and Prevention. From 2013 to 2015, he worked as a Research Fellow at the University of Washington School of Medicine and the Asia-Pacific Research Center at Stanford University. Over the past five years, he has published nearly 50 original articles as first or corresponding author in journals including JAMA, BMJ, JAMA Cardiology, and the Lancet family journals. His work focuses on management of heart failure, as well as clinical research methodology, real world evidence, and cross border trial coordination. In 2025, his H index reached 57, and he has been consecutively listed in Stanford University's World's Top 2% Most Cited Scientists from 2022 to 2025. He currently serves as Director of the BAY TRIAL, leading efforts to build a bidirectional clinical research gateway between China and the global community.

PATHFINDING CHINA: CLINICAL RESEARCH & LIFE SCIENCES AHEAD



Andrew Stephen Lee

• Deputy Director

**Hong Kong-Macau-Guangdong
GBA International Clinical Trial
Center (BAY TRIAL)**

TITLE OF THE TALK:

Clinical Development of a Non-Viral Extracellular Vesicle Therapy Gene Therapy for Rare Disease via the 818 Dual Track Regulatory Framework in China

ABSTRACT:

The success of gene therapy relies on delivery systems that enable safe, targeted, and stable translation of genetic material into functional proteins. Here we describe the development process to translate a novel extracellular vesicle gene therapy platform to first in human clinical trials in China via the new 818 dual track regulatory framework.

BIOGRAPHY:

Andrew Lee, MD, PhD, is an Associate Professor at Peking University Shenzhen / Shenzhen Bay Laboratory, and Deputy Director of the HK-Macau-Guangdong GBA International Clinical Trial Center. He earned his B.S. from Yale and MD/PhD from Stanford, where he completed residency in Clinical Pathology with a focus on cell gene therapy clinical trials. His work focuses on clinical translation of non-viral gene therapies for treatment of rare disease, with over 60 publications in Cell, Nature Medicine, Nature Biotechnology, Nature Biomedical Engineering and JAMA, cited over 12,000 times (H-index 47).

PATHFINDING CHINA: CLINICAL RESEARCH & LIFE SCIENCES AHEAD



Tan Sze-Wee

- Advisor, Temasek Singapore Pte Ltd
- Adjunct Professor, Duke-NUS Medical School, Singapore
- Chairman, NUS Medicine Industry Advisory Board, Singapore

Temasek Singapore Pte Ltd
Ecosystem Enablement

Duke - NUS Medical School, Singapore
Adjunct Professor

NUS Medicine Industry Advisory Board, Singapore

TITLE OF THE TALK:

Overview Of Life Sciences Ecosystem in China - Biosparc as Singapore's Gateway to China

ABSTRACT:

There is rapid development in the lifesciences and healthcare sector in China, Singapore is also positioning itself as a regional regulatory platform. This sharing will provide information on how BioSparc - which acts as the China-Singapore Lifesciences Corridor between Suzhou Industrial Park and Singapore, can facilitate further partnership between both countries.

BIOGRAPHY:

Currently serving as Advisor, Ecosystem Enablement (Healthcare & Lifesciences), Temasek Singapore Pte Ltd, **Sze-Wee** plays a pivotal role in shaping cross-border biomedical innovation and investment strategy. His work includes advancing Temasek's involvement in BioSparc, a flagship initiative jointly developed with Suzhou Industrial Park (SIP), designed to anchor the China-Singapore Life Sciences Corridor.

In this capacity, he is leading the development of a bi-directional platform that enables high-potential Chinese biotech companies to leverage Singapore's regulatory strength, global connectivity, and commercialization capabilities, while providing international life sciences companies with structured access to China's innovation ecosystem. This effort represents a first-of-its-kind Sze-Wee has held multiple senior leadership roles across Singapore's innovation ecosystem, including overseeing national biomedical and engineering research strategies, directing multi-billion-dollar R&D; portfolios, and advancing commercialization pipelines through strong public-private partnership.

Sze-Wee holds an Adjunct Professorship at Duke-NUS Medical School and continues to contribute actively to academic, policy, and industry discourse. He previously served as a Nominated Member of Parliament in Singapore and is a recipient of multiple national honors, including the Public Administration Medal (Silver). He holds an MBBS from the National University of Singapore, an MBA from the University of Warwick, and has completed Executive Education at Stanford Graduate School of Business.



SPONSORS & ORGANIZERS

Main Organizer:

**NUS**
National University
of SingaporeYong Loo Lin
School of Medicine

Symposium Co-organizers:

**上海交通大学医学院**

SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE

MANCHESTER
1824

The University of Manchester

**浙江大学 医学院**SCHOOL OF MEDICINE
ZHEJIANG UNIVERSITY

Organizing Partner:



无锡市创新投资集团有限公司
 WUXI CAPITAL GROUP CO., LTD.

Wuxi Capital Group Co., Ltd. ("Wuxi Capital Group") is a state-owned venture capital institution spanning the entire investment lifecycle, from seed, angel, and venture funding to growth equity, M&A, and secondary funds. The company has evolved into a leading integrated investment platform.

Driven by a commitment to reform and innovation, Wuxi Capital Group continues to integrate resources and refine its investment system while exploring market-oriented mechanisms. It owns or controls several key investment entities, including Jintou Capital, Guolian Industrial Investment, Guolian Capital, Huallywood Investment, Wuxi Zhanxin and V-Capital, and maintains strategic offices in Beijing, Shanghai, Shenzhen, and Singapore.

With a long-term perspective and disciplined investment approach, the company has built a robust fund ecosystem supporting enterprises across all growth stages. Managing over RMB 300 billion in assets, it delivers tailored financial solutions for innovation and industrial growth, focusing on strategic emerging sectors such as biomedicine, artificial intelligence, integrated circuits, aerospace, advanced manufacturing, and new energy. Its self-managed funds have invested in over 1,000 enterprises, supporting the listing of more than 110 companies, including NCE Power, Angelalign, and Zhongjie Precision.

Wuxi Capital Group played a leading role in implementing the RMB 73.75 billion Phase II China State-Owned Enterprise Structural Adjustment Fund and manages a RMB 1.5 billion municipal angel investment fund, helping shape a world-class domestic equity investment ecosystem. It has also supported landmark projects such as Hua Hong (Wuxi) and Wingtech Technology, forging synergy between finance, technology, and industry. It keeps growing with its partners.



Strategic Partners:



Illumina is a global leader in DNA sequencing and array-based technologies, dedicated to improving human health by unlocking the power of the genome. Founded in 1998 and headquartered in San Diego, California, Illumina provides products and services to more than 9,500 customers worldwide. As of the end of 2025, Illumina had an active installed base of 21,000 instruments globally.

China is one of Illumina's most important markets globally. Since entering the China market in 2005, Illumina has continued to strengthen its commitment to China and accelerate its localization journey. In 2022, Illumina's Greater China headquarters was recognized by the Shanghai Municipal Commission of Commerce as a regional headquarters of a multinational company. In the same year, Illumina's China manufacturing site officially began operations, further demonstrating the company's determination to deepen its presence in the China market and its confidence in continually upgrading its localization footprint. In 2023, with the official launch of locally manufactured sequencers and reagents, Illumina took an even more substantial step forward in its development in China. In 2025, Illumina established a Beijing Customer Engagement Center and launched its official e-commerce platform, MyIllumina, creating a closed-loop omnichannel service model to provide local customers with high-quality services and products. In 2026, Illumina introduced the Illumina Bioinformatics Mobile Workstation, a mobile deployment model designed to bring DRAGEN™-powered high-performance computing closer to where research is conducted.



Strategic Partners:



Book meeting
with our team



预约与我们
团队见面

Bredis Healthcare is a leading biomarker-focused clinical laboratory and translational research company specializing in ultrasensitive immunoassays, proteomics, and multimodal biomarker research. Operating under GCLP-compliant quality systems, Bredis supports biomarker discovery, ICH guideline-compliant clinical trials, precision medicine, and global multicenter studies in neurodegenerative diseases, CNS disorders, inflammation, oncology, and aging.

Founded in 2023, Bredis has rapidly become Asia's leading laboratory for blood-based biomarkers of neurodegenerative diseases and serves as the exclusive biomarker analysis partner for the GARD cohort, Asia's largest longitudinal dementia and healthy aging cohort. The company collaborates extensively with academic institutions, hospitals, pharmaceutical companies, and biotechnology partners across Asia.

Its GCLP-certified cleanroom laboratory operates both the Alamar ARGO HT and Quanterix Simoa HD-X platforms, offering more than 580 protein biomarkers, including pTau217, eMTBR-tau, GFAP, NfL, inflammatory proteins, oncology markers, and multiplex proteomics panels. Bredis also provides custom assay development, IVD commercialization support, and performs approximately 50,000 biomarker tests annually as Asia's first Alamar Biosciences Certified Service Provider (CSP).

Beyond laboratory services, Bredis integrates blood biomarkers with wearable-derived digital phenotyping through its AI-powered precision medicine platform. In 2026, the company established the BRAIN (Bredis Research Center for Aging and Integrated Neuroscience) with the National University of Singapore to build an Asia-wide collaborative network advancing biomarker validation, multicenter clinical research, and precision neurology.

Book a time to meet with us during the Partnership Week!



Supporting & Community Partners:



NUS MEDICINE • CHINA ACADEMIC PARTNERSHIP SUMMIT

